ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: A novel two-hit, sparing-material approach

Journal of Thoracic Oncology

Volumn 7, Issue 2, 2012, Pages 281-290

  Pelosi, Giuseppe ^a,b   Fabbri, Alessandra ^a   Bianchi, Fabrizio ^a,c   Maisonneuve, Patrick ^d   Rossi, Giulio ^e   Barbareschi, Mattia ^f   Graziano, Paolo ^g   Cavazza, Alberto ^h   Rekhtman, Natasha ⁱ   Pastorino, Ugo ^a   Scanagatta, Paolo ^a   Papotti, Mauro ^j  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f SANTA CHIARA HOSPITAL   (Italy)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Biopsy; Cellblock; Diagnosis; Immunohistochemistry; Morphology; NSCLC; P40; P63; Surgical specimen; TTF1

Indexed keywords

PROTEIN P40; THYROID TRANSCRIPTION FACTOR 1;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; SARCOMATOID CARCINOMA;

EID: 84858342603     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31823815d3     Document Type: Article

References (67)

1. Smith BR. Therapeutic pathology: time to move beyond diagnostics. Hum Pathol 2008;39:1725-1727.
2. Rossi G, Pelosi G, Graziano P, et al. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol 2009;17:206-218.
3. Kerr K. Pulmonary adenocacarcinomas: classification and reporting. Histopathology 2009;54:12-27.
4. Pelosi G, Sonzogni A, Viale G. The classification of lung carcinoma: time to change the morphology-based approach? Int J Surg Pathol 2010;18:161-172.
5. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411-414.
6. Wallace W. The challenge of classifying poorly differentiated tumours of the lung. Histopathology 2009;54:28-42.
7. Hirsch FR, Wynes MW, Gandara DR, et al. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res 2010;16:4909-4911.
8. Pelosi G, Rossi G, Bianchi F, et al. Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, TTF1, vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 2011;6:1039-1049.
9. Pelosi G. The new taxonomy of lung adenocarcinoma stemming from a multidisciplinary integrated approach: novel pathology concepts and perspectives. J Thorac Oncol 2011;6:241-243.
10. Travis W, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244-285.
11. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011;6:451-458.
12. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 2001;25:363-372. (Pubitemid 32175139)
13. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-773. (Pubitemid 34546942)
14. Stenhouse G, Fyfe N, King G, et al. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol 2004;57:383-387. (Pubitemid 38446256)
15. Reis-Filho JS, Carrilho C, Valenti C, et al. Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas? Pathol Res Pract 2000;196:835-840. (Pubitemid 32037242)
16. Downey P, Cummins R, Moran M, et al. If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS 2008;116:526-529.
17. Okuyama R, Ogawa E, Nagoshi H, et al. p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity. Oncogene 2007;26:4478-4488. (Pubitemid 47037037)
18. Yang A, Zhu Z, Kettenbach A, et al. Genome-wide mapping indicates that p73 and p63 co-occupy target sites and have similar DNA-binding profiles in vivo. PLoS One 2010;5:e11572.
19. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-718. (Pubitemid 29197650)
20. Nekulova M, Holcakova J, Coates P, et al. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett 2011;16:296-327.
21. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010;29:23-36.
22. Pelosi G, Pasini F, Olsen Stenholm C, et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 2002;198:100-109. (Pubitemid 34966213)
23. Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999;12:5-8. (Pubitemid 29059159)
24. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002;33: 175-182. (Pubitemid 34298732)
25. Sturm N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001;32:918-925. (Pubitemid 32911313)
26. La Rosa S, Chiaravalli AM, Placidi C, et al. TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch 2010;457:497-507.
27. Bishop P. An immunohistochemical vade mecum. Available at: http://e-immunohistochemistry.info/web/histopathology-help.htm. Accessed October 2011.
28. Hibi K, Nakayama H, Taguchi M, et al. AIS overexpression in advanced esophageal cancer. Clin Cancer Res 2001;7:469-472. (Pubitemid 32707966)
29. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 2000;97:5462-5467. (Pubitemid 30313741)
30. Senoo M, Tsuchiya I, Matsumura Y, et al. Transcriptional dysregulation of the p73L/p63/p51/p40/KET gene in human squamous cell carcinomas: expression of Delta Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51. Br J Cancer 2001;84:1235-1241. (Pubitemid 32511342)
31. Yamaguchi K, Wu L, Caballero OL, et al. Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int J Cancer 2000;86:684-689. (Pubitemid 30249880)
32. Iwata T, Uramoto H, Sugio K, et al. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer. Lung Cancer 2005;50:67-73. (Pubitemid 41297471)
33. Morita M, Uramoto H, Nakata S, et al. Expression of deltaNp63 in squamous cell carcinoma of the esophagus. Anticancer Res 2005;25: 3533-3539. (Pubitemid 41105237)
34. Uramoto H, Sugio K, Oyama T, et al. Expression of the p53 family in lung cancer. Anticancer Res 2006;26:1785-1790. (Pubitemid 43989432)
35. Uramoto H, Yamada S, Hanagiri T. Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res 2010;30: 4717-4720.
36. Pelosi G, Sonzogni A, Papotti M, et al. Different prevalence of transactivating (TA) p63 and non-TAp63 isoforms in pulmonary adenocarcinomas: a useful diagnostic tool. Mod Pathol 2010;23:396A-415A.
37. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011;117:3416-3423.
38. Wang BY, Gil J, Kaufman D, et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 2002;33:921-926.
39. Travis W, Brambilla E, Muller-Hermelink H, et al. Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
40. Pelosi G, Fraggetta F, Nappi O, et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth and tumor cell motility: a clinicopathological and immunohistochemical study of 31 cases. Am J Surg Pathol 2003;27:1203-1215. (Pubitemid 37040582)
41. Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010; 18:103-120.
42. Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. New York: Wiley-Blackwell; 2010.
43. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5:442-447.
44. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010;5:436-441.
45. Cakir E, Demirag E, Aydin M, et al. Clinicopathologic features and prognostic significance of lung tumours with mixed histologic patterns. Acta Chir Belg 2009;109:489-493.
46. Cooke DT, Nguyen DV, Yang Y, et al. Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg 2010;90:943-948.
47. Filosso PL, Ruffini E, Asioli S, et al. Adenosquamous lung carcinomas: a histologic subtype with poor prognosis. Lung Cancer 2011;74:25-29.
48. Mukhopadhyay S, Katzenstein AL. Subclassification of Non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, Napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25.
49. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805-1811.
50. Bishop Y, Fienberg S, Holland P. Discrete Multivariate Analysis: Theory and Practice. Cambridge, Massachusetts: MIT Press; 1975.
51. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 2010;5:1315-1316.
52. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med 2008;132:384-396. (Pubitemid 351328813)
53. Rosai J. Why microscopy will remain a cornerstone of surgical pathology. Lab Invest 2007;87:403-408. (Pubitemid 46633129)
54. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162.
55. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-664.
56. Ries L, Eisner M. Cancer of the Lung. Bethesda: NIH; 2007.
57. Munfus-McCray D, Harada S, Adams C, et al. EGFR and KRAS mutations in metastatic lung adenocarcinomas. Hum Pathol 2011;42: 1447-1453.
58. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011;24:1348-1359.
59. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011;32:22-31.
60. Pelosi G, Scarpa A, Manzotti M, et al. K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004;17:538-546. (Pubitemid 38868420)
61. Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004;122:884-893. (Pubitemid 39577356)
62. Rossi G, Papotti M, Barbareschi M, et al. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol 2009;27:e141-e142; author reply e3-e4.
63. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011; 35:1226-1234.
64. Sridhar KS, Raub WA Jr, Duncan RC, et al. The increasing recognition of adenosquamous lung carcinoma (1977-1986). Am J Clin Oncol 1992;15:356-362.
65. McDowell EM, Trump BF. Pulmonary small cell carcinoma showing tripartite differentiation in individual cells. Hum Pathol 1981;12:286-294. (Pubitemid 11156003)
66. Nishimaki T, Nakagawa S, Aizawa K, et al. Composite tumor of the esophagus with tripartite differentiation. Dig Dis Sci 1997;42:1041-1046. (Pubitemid 27239798)
67. Pardo J, Martinez-Penuela AM, Sola JJ, et al. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol 2009;17:383-392.